Both CD163 and CD4 + CXCR5 can be regarded as prognostic predictors for CRC patients to facilitate the evaluation of cancer prognosis and TME status, thereby optimizing individualized treatment plans and improving cancer patient survival. The gene discussed is CD163; the disease is colorectal carcinoma.